Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

IMIPRAMINE PAMOATE

IMIPRAMINE PAMOATE

Standard Dose
EQ 75MG HYDROCHLORIDE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview IMIPRAMINE PAMOATE is listed in Drugs@FDA under application 202338 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient IMIPRAMINE PAMOATE Form and strength CAPSULE;ORAL - EQ 75MG HYDROCHLORIDE Sponsor RISING Submission history Latest submission status date: 2025-06-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview IMIPRAMINE PAMOATE is listed in Drugs@FDA under application 202338 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient IMIPRAMINE PAMOATE Form and strength CAPSULE;ORAL - EQ 75MG HYDROCHLORIDE Sponsor RISING Submission history Latest submission status date: 2025-06-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.